Elevance Health (ELV) insider buying and selling
Every Table I transaction reported by directors and officers of S&P 500 companies on SEC Form 4 filings (2 business days to file): each row labeled with its official transaction code, nothing filtered out beforehand.
Open-market purchases (code P) are the rare signal, in green; sales (code S) are common and often pre-scheduled (10b5-1). Table II (derivatives) is not included: its prices are exercise prices, not market values. Guide: insider buying.
| Date | Ticker | Insider | Role | Shares | Price | Amount | % of stake | Type / filing |
|---|
Download these transactions as CSV No account, no sign-up. The data is public: it comes from SEC Form 4 filings.
Elevance Health, Inc. (ELV) insider buying and selling: 3 purchases, 5 sales
56 Form 4 Table I transactions filed with the SEC by Elevance Health, Inc. insiders between 2025-09-04 and 2026-10-06 (15-month history): 3 open-market purchases and 5 sales, plus 48 transactions under other Form 4 codes, broken down one by one below. The largest open-market trade is a purchase of $1.0M by Boudreaux Gail on 2026-07-17.
Elevance Health insider buying and selling over the last 12 months
Between Oct 21, 2025 and Oct 20, 2026, Elevance Health insiders filed 3 purchases worth $2.2M and 5 sales worth $1.7M on the open market. The net balance is on the buy side: $493k more bought than sold.
The biggest buyer was Boudreaux Gail (President and CEO): $1.0M in 1 purchase, out of 3 different buyers. The biggest seller was Kendrick Charles Morgan Jr (EVP & President, Commercial): $911k in 1 sale, out of 4 different sellers.
The largest trade of the period was a purchase of $1.0M on Jul 17, 2026, by Boudreaux Gail (President and CEO). Form 4 on sec.gov (0001287920-26-000006).
None of the 5 sales carries the 10b5-1 plan flag on the Form 4 (sales scheduled months ahead).
The last three months show 0 purchases and 0 sales, against 2 and 3 in the three before. The latest purchase is from Jul 17, 2026; the latest sale from Jun 12, 2026.
Against its sector (Healthcare, 59 companies with an insider page on this site), over the same dates the median is 9 sales and 0 purchases on the open market. Elevance Health has more sales than 18 of the other 58, ranks 5 of 59 by net dollars bought, and 19 of the 59 have at least one purchase, Elevance Health included.
The 20 most important trades
The 3 open-market purchases first, then the rest, each type from largest to smallest. The full history is in the tool above, already searched.
See all 56 ELV trades in the full history →
| Trade date | Filed | Insider | Role | Amount | Code | Filing |
|---|---|---|---|---|---|---|
| 2026-07-17 | 2026-07-17 | Boudreaux Gail | President and CEO | $1.0M | P — Open-market purchase2 Form 4 footnotesF1 This transaction was executed in multiple purchases at prices ranging from $366.14 to $366.48. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2 This transaction was executed in multiple purchases at prices ranging from $367.76 to $368.69. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-03-05 | 2026-03-06 | Collis Steven H | Director | $870k | P — Open-market purchase | SEC |
| 2026-07-17 | 2026-07-17 | Peru Ramiro G | Director | $366k | P — Open-market purchase | SEC |
| 2026-03-06 | 2026-03-09 | Kendrick Charles Morgan Jr | EVP & President, Commercial | $911k | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $284.82 to $285.08. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-05-19 | 2026-05-20 | Penczek Ronald W | CAO & Controller | $617k | S — Open-market saleForm 4 footnoteF2 This transaction was executed in multiple trades, each at the same price of $403.13. | SEC |
| 2026-06-12 | 2026-06-15 | Penczek Ronald W | CAO & Controller | $149k | S — Open-market saleForm 4 footnoteF1 This transaction was executed in multiple trades at prices ranging from $403.15 to $403.31. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. | SEC |
| 2026-06-11 | 2026-06-12 | Dixon Robert L Jr | Director | $61k | S — Open-market sale | SEC |
| 2026-03-12 | 2026-03-23 | Schulman Amy W | Director | $7k | S — Open-market sale | SEC |
| 2026-03-02 | 2026-03-04 | Boudreaux Gail | President and CEO | $2.0M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-10-02 | 2026-10-06 | Kaye Mark | EVP & CFO | $1.6M | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2025-10-02 | 2025-10-03 | Kaye Mark | EVP & CFO | $985k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-03 | 2026-03-04 | Boudreaux Gail | President and CEO | $493k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-05-19 | 2026-05-20 | Penczek Ronald W | CAO & Controller | $451k | M — Option exerciseForm 4 footnoteF1 Balance includes 10.21 shares acquired on March 25, 2026 through a dividend reinvestment plan. | SEC |
| 2026-03-02 | 2026-03-04 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | $418k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-02 | 2026-03-04 | Kendrick Charles Morgan Jr | EVP & President, Commercial | $356k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-02 | 2026-03-04 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | $353k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-03 | 2026-03-04 | Norwood Felicia F | EVP &Chief Health Benefits Ofr | $141k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-03 | 2026-03-04 | Kendrick Charles Morgan Jr | EVP & President, Commercial | $133k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-03 | 2026-03-04 | Haytaian Peter D | EVP & Pres Carelon & CarelonRx | $127k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF1 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
| 2026-03-03 | 2026-03-04 | Wessling Erin M | EVP & Chief Legal Officer | $118k | F — Tax withholding (shares surrendered for taxes)Form 4 footnoteF2 PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. | SEC |
The period balance: money in, money out
Across the Form 4 filings submitted between Sep 4, 2025 and Oct 6, 2026, Elevance Health, Inc. open-market activity adds up to 3 purchases worth $2.2M and 5 sales worth $1.7M. The net balance is $493k on the buy side.
Only codes P and S count, where an insider puts in or takes out their own money. A buying balance like Elevance Health, Inc.'s is the less common case in the S&P 500: its insiders are already paid in stock and still put in their own money. It is not a recommendation to buy or sell: it is what was filed.
Every transaction, code by code
| Code | What it means | Trades | Reported amount |
|---|---|---|---|
| F | Tax withholding (shares surrendered for taxes) | 24 | $7.5M |
| A | Grant or award | 23 | $0 |
| S | Open-market sale | 5 | $1.7M |
| P | Open-market purchase | 3 | $2.2M |
| M | Option exercise | 1 | $451k |
| Total | Everything filed in the period | 56 | $12.0M |
23 of the 56 rows carry no usable amount on the Form 4: they count as trades and add $0. The code labels come from the SEC index.
Who has traded
Over the 15 months of history, 19 distinct people or entities have filed Elevance Health, Inc. transactions: 3 bought on the open market and 4 sold. Counted by CIK, the fixed number the SEC gives each filer, and not by name, which each filer types their own way.
| Filer | Role | Transactions | Bought (count) | Sold (count) | Last filed |
|---|---|---|---|---|---|
| Boudreaux Gail | President and CEO | 4 | $1.0M (1) | — | 2026-07-17 |
| Kendrick Charles Morgan Jr | EVP & President, Commercial | 4 | — | $911k (1) | 2026-03-09 |
| Collis Steven H | Director | 2 | $870k (1) | — | 2026-05-15 |
| Penczek Ronald W | CAO & Controller | 6 | — | $766k (2) | 2026-06-15 |
| Peru Ramiro G | Director | 2 | $366k (1) | — | 2026-07-17 |
| Dixon Robert L Jr | Director | 2 | — | $61k (1) | 2026-06-12 |
| Schulman Amy W | Director | 3 | — | $7k (1) | 2026-05-15 |
| Craig Ryan R | EVP & Chief HR Officer | 6 | — | — | 2026-09-04 |
Shown here are the 8 who moved the most money, out of 19. The rest are in the full history, one link above. The name links to all their trades, in any company. "Transactions" counts any code; the money, open market only. Role: from their latest filing.
Month by month
By the month the trade was executed, not the month it was filed; months with no trades show zero. The busiest month was Mar 2026: 1 purchase and 2 sales, worth $1.8M. 11 of the 15 months have none.
| Month | Purchases | Amount | Sales | Amount |
|---|---|---|---|---|
| Aug 2025 | 0 | $0 | 0 | $0 |
| Sep 2025 | 0 | $0 | 0 | $0 |
| Oct 2025 | 0 | $0 | 0 | $0 |
| Nov 2025 | 0 | $0 | 0 | $0 |
| Dec 2025 | 0 | $0 | 0 | $0 |
| Jan 2026 | 0 | $0 | 0 | $0 |
| Feb 2026 | 0 | $0 | 0 | $0 |
| Mar 2026 | 1 | $870k | 2 | $918k |
| Apr 2026 | 0 | $0 | 0 | $0 |
| May 2026 | 0 | $0 | 1 | $617k |
| Jun 2026 | 0 | $0 | 2 | $209k |
| Jul 2026 | 2 | $1.4M | 0 | $0 |
| Aug 2026 | 0 | $0 | 0 | $0 |
| Sep 2026 | 0 | $0 | 0 | $0 |
| Oct 2026 | 0 | $0 | 0 | $0 |
The last month may be partial: a Form 4 is filed up to two business days later. The table does not say whether the pattern is good or bad; it says when it happened.
Elevance Health, Inc. (ELV) analysis page →
Other Healthcare companies with insider trades
All 500 are listed in the section index →
Which insiders are buying their own company stock →
How to read this data
None of the 5 sales in the table is flagged as scheduled (10b5-1 plan), the kind signed months ahead and executed automatically. Elevance Health's 3 open-market purchases (code P) are the rare signal: insiders are already paid in stock, so buying more means putting in their own money. The latest filing is from Oct 6, 2026, and a Form 4 arrives up to two business days after the trade.
16 of the 20 rows in the table carry footnotes from the Form 4 itself, folded into the code column and copied verbatim; a row with no footnote means the filing has none.
Guide: Insider buying · all guides
What is behind these trades
The concepts on this page, explained from scratch in the Academy. Free, no account.
- What the efficiency hypothesis says and what it does NOT sayIf an insider's purchase is public and anyone can read it, is there any information left in it? That is the exact question that brings people here.
- Who really moves the market: the types of investorWho sits on the other side of each order, and where a company's own insiders fit among them.
- Supply, demand and price: why it rises and falls constantlyHow a piece of news ends up inside the price, and why the reaction to a filed sale is rarely the one you would expect.
Source: SEC EDGAR Form 4. This is a list of public facts, not financial advice or a recommendation to buy or sell.